Filing Details
- Accession Number:
- 0001104659-19-039829
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-10 16:15:21
- Reporting Period:
- 2019-07-08
- Accepted Time:
- 2019-07-10 16:15:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1722964 | Y-Mabs Therapeutics Inc. | YMAB | Pharmaceutical Preparations (2834) | 474619612 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1753224 | Thomas Gad | C/O Y-Mabs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York NY 10169 | President And Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-07-08 | 4,000 | $22.40 | 912,000 | No | 4 | S | Indirect | By GAD Enterprises LLC |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By GAD Enterprises LLC |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,030,557 | Indirect | By WG Biotech ApS |
Footnotes
- Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2019.
- This transaction was executed in multiple trades at prices ranging from $22.76 to $21.90. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
- WG Biotech ApS owns 5,010,000 shares of the Issuer's common stock. GAD Enterprises, LLC (of which Reporting Person is sole member) owns 20.57% of WG Biotech ApS but has no voting or dispositive power over the shares of common stock held by WG Biotech ApS.